Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The total artificial heart: where we stand.

O H Frazier1, Robert D Dowling, Laman A Gray

  • 1Cardiopulmonary Transplant Service, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA. knowlin@heart.thi.tmc.edu

Cardiology
|February 28, 2004
PubMed
Summary

The AbioCor total artificial heart (TAH) shows promise for end-stage heart failure patients, offering reliable support and improved quality of life. Thromboembolism is a challenge, but infection is reduced due to its totally implantable design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fate of dilated ascending aorta after transcatheter aortic valve replacement.

JTCVS structural and endovascular·2026
Same author

Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics.

British journal of biomedical science·2026
Same author

Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor-Positive Recipient-Negative Mismatched Heart Transplant Recipients: An Observational Study.

Clinical transplantation·2025
Same author

Evaluation of warfarin dose and INR time in therapeutic range in left ventricular assist device patients with sleeve gastrectomy.

The International journal of artificial organs·2025
Same author

Coronary flow capacity and survival prediction after revascularization: physiological basis and clinical implications.

European heart journal·2023
Same author

Comparison of survival by vasoactive-inotropic score in patients receiving veno-arterial extracorporeal life support.

The International journal of artificial organs·2023

Area of Science:

  • Cardiovascular Surgery
  • Biomedical Engineering
  • Regenerative Medicine

Background:

  • End-stage congestive heart failure (CHF) significantly impacts quality of life and survival.
  • Heart transplantation is limited by donor availability.
  • Destination therapy offers an alternative for patients ineligible for transplantation.

Purpose of the Study:

  • To evaluate the clinical feasibility of the AbioCor total artificial heart (TAH) as destination therapy.
  • To assess the safety and efficacy of the TAH in patients with end-stage CHF.
  • To explore the potential of TAH as an alternative to heart transplantation.

Main Methods:

  • Feasibility testing of the AbioCor TAH in 11 patients with end-stage CHF.
  • Monitoring device reliability, circulatory support, survival, and quality of life.

Related Experiment Videos

  • Investigating adverse events such as thromboembolism and infection.

    • Main Results:

    • The AbioCor TAH demonstrated reliable performance, providing adequate circulatory support.
    • Most recipients experienced extended survival and improved quality of life.
    • Thromboembolism was identified as a significant issue, while infection rates were minimized due to the totally implantable nature of the device.

    Conclusions:

    • The AbioCor TAH shows potential as an alternative to heart transplantation for selected CHF patients.
    • Further research is needed to address thromboembolism and optimize patient management.
    • The device's size limits its applicability in smaller patients, necessitating the development of a smaller version.